ArticleBMC pulmonary medicine2022
Old age is associated with worse treatment outcome and frequent adverse drug reaction in Mycobacterium avium complex pulmonary disease.
Article in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Radiographic severity and treatment optimisation inERJ open research · 2026Article
- Clinical outcomes and adverse events of nontuberculous mycobacterial lung disease treated at an Italian tertiary referral center.Scientific reports · 2025Observational
- Epidemiology and Drug Susceptibility of Nontuberculous Mycobacteria in the Province of Pavia (Northern Italy): An Overview.Microorganisms · 2025Article
- Considerations in the Diagnosis and Management of Bronchiectasis in Older Adults.Clinics in geriatric medicine · 2025Review
- Clinical Implications of Time to Culture Conversion inOpen forum infectious diseases · 2025Article
- TheMicroorganisms · 2025Review
- Multicentre retrospective observational study for development and validation of MAC prognostic score model.Scientific reports · 2025Observational
- Relationship between age, sex, geography and incidence of nontuberculous mycobacteria in Denmark from 1991 to 2022.ERJ open research · 2025Article
- Tolerability and efficacy of Mycobacterium avium complex pulmonary disease treatment in elderly patients.BMC pulmonary medicine · 2025Article
- Protein-energy restriction-induced lipid metabolism disruption causes stable-to-progressive disease shift in Mycobacterium avium-infected female mice.EBioMedicine · 2024Article
- Trends in Non-Tuberculous Mycobacterial Lung Disease and Treatment Outcomes in a Low-Tuberculosis Prevalence Setting: A Retrospective Analysis.Pathogens (Basel, Switzerland) · 2024Article
- Intracellular iron accumulation facilitates mycobacterial infection in old mouse macrophages.GeroScience · 2024Article
- Clinical course of nontuberculous mycobacterial pulmonary disease in patients with rheumatoid arthritis.Advances in rheumatology (London, England) · 2024Article
- Treatment Outcomes of Clofazimine-Containing Regimens in SevereOpen forum infectious diseases · 2024Article
- Risk factors for microbiological persistence after 6 months of treatment forMicrobiology spectrum · 2023Article
- Adjuvant surgical resection for nontuberculous mycobacterial pulmonary disease: Effectiveness and complications.Annals of thoracic medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe number of patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) is rapidly increasing globally, especially in the older population. However, there is a dearth of evidence regarding the impact of aging on the treatment outcomes of NTM-PD.
methodsWe analyzed consecutive patients who satisfied the diagnostic criteria for Mycobacterium avium complex (MAC)-PD and received antibiotic treatment between January 2009 and December 2020 at a tertiary referral hospital in Korea. The main outcomes were (1) long-term treatment success, defined by negative culture conversion for more than 12 months; and (2) adverse drug reactions (ADRs). Multivariable logistic regression model was used to evaluate the association between age and main outcomes.
resultsA total of 614 patients (median age, 65 years, interquartile range [IQR] 57-73 years; men, 35.3%) were included. Median treatment duration (530 days, IQR 290-678 days; P for trend < 0.001) and long-term treatment success (P for trend = 0.026) decreased, whereas ADRs (P for trend < 0.001) increased significantly with age. Multivariable analyses demonstrated that age ≥ 80 years was an independent factor associated with ADRs (adjusted odds ratio [aOR] 3.29; 95% confidence interval [CI] 1.05-10.28) and worse treatment outcome (aOR 0.42; 95% CI 0.19-0.91).
conclusionsAging is associated with worse treatment outcome and frequent ADRs of patients with MAC-PD. Individualized treatment with reduced-intensity may be a reasonable alternative for older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.